Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Sildenafil in Mild COPD
NCT05061368Phase 2Recruiting
- Sponsor
- University of Alberta
- Start
- Mar 2022
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ASP-001 in chronic obstructive pulmonary disease (COPD), sponsored by University of Alberta. Started Mar 2022; status: recruiting.
02
Drugs
ASP-001
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT05061368.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05061368.